November 03, 2026

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

To
The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Sub: Investor Presentation for Q2 FY27 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on Financial Results for quarter and half year ended September 30, 2026, which would be used in the Investors / Analysts earnings conference call scheduled to be held on **Wednesday, November 04, 2026, at 11:00 A.M. (IST).**

Please take the information on record.

Thanking you.

Yours faithfully,
For **Vijaya Diagnostic Centre Limited**

KOLUKULURI APPALA NARASIMHA RAJU
Digitally signed by KOLUKULURI APPALA NARASIMHA RAJU

Narasimha Raju K A
Chief Financial Officer
Encl.: As Above



Q2 & H1 FY27 Earnings Presentation

November 3, 2026

Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Vijaya Diagnostic Centre Limited (the 'Company')**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



VIJAYA DIAGNOSTIC CENTRE®

Q2 FY27 & H1 FY27 Performance Snapshot

Q2 FY27 Performance Snapshot

Financial Performance

INR 2,554 Mn
Revenue from Operations

INR 1,128 Mn | 44.1%
EBITDA | EBITDA Margin %

INR 595 Mn | 23.3%
PAT | PAT Margin %

Key Metrics

1.37 Mn
Footfall

4.98 Mn
Tests

168
Centres

92%
B2C Revenue %

YOY Growth %

26.7% Revenue Growth %


16.5% Test Volume Growth %

14.5% Footfall Growth %


37.8% EBITDA Growth %

37.4% PAT Growth %

Geographical Contribution



Wellness Share%



H1 FY27 Performance Snapshot

Financial Performance

INR 4,864 Mn
Revenue from Operations

INR 2,113 Mn | 43.4%
EBITDA | EBITDA Margin %

INR 1,126 Mn | 23.1%
PAT | PAT Margin %

Key Metrics

2.61 Mn
Footfall

9.57 Mn
Tests


168
Centres

92%
B2C Revenue %


YOY Growth %

24.8% Revenue Growth %	16.5% Test Volume Growth %	13.7% Footfall Growth %
36.0% EBITDA Growth %	37.5% PAT Growth %	

Geographical Contribution



Wellness Share%



Management Commentary



Commenting on the Q2 FY27 & H1 FY27 results and future business outlook, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said:

"I am pleased to share that we have sustained our strong growth momentum during Q2 FY27, delivering 26.7% year-on-year revenue growth, supported by 16.5% volume growth. Our existing centres grew by approximately 20%, while newer centres continued to ramp up well. Our core markets maintained strong momentum, while Pune has been witnessing a meaningful turnaround with consistent double-digit growth since few quarters.

We continue to see encouraging momentum in West Bengal, as our brand awareness strengthens. We are particularly pleased with the response in Tier-II markets such as Krishnanagar and Diamond Harbour.

On the expansion front, we have commissioned 2 hubs and 7 spokes so far during FY27. Looking ahead, we expect to commission another 3 hubs & 7 spokes in H2 FY27, followed by 3 additional hubs in Q1 FY28, further strengthening our network and expanding our presence across key markets.

During the quarter, we entered into Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam. This marks our entry into the North-East region and is an important step towards expanding our geographical presence beyond our existing markets. We believe this acquisition provides us with a strong platform to establish our presence in Guwahati and gradually explore further growth opportunities across the North-East, leveraging our expertise in integrated diagnostics and operational excellence.


We remain committed to strengthening our presence across key markets, investing in advanced technology and delivering high-quality diagnostic services to support sustainable long-term growth."

Key Financial Highlights


(INR Mn)

Key Financials


Revenue from Operations



EBITDA & EBITDA Margin %




PAT & PAT Margin %




Revenue Mix


Radiology vs. Pathology Breakdown %



B2C Revenue %




Wellness share %




Key Operational Highlights


Tests Performed (# in Mn)




Footfalls (# in Mn)




Tests / Footfalls (#)



Revenue per Test (INR)



Revenue per Footfall (INR)



Consolidated Profit & Loss Statement

(INR Mn)

Particulars	Q2 FY27	Q2 FY26	Y-o-Y	Q1 FY27	Q-o-Q	H1 FY27	H1 FY26	Y-o-Y
Revenue from operations	**2,553.9**	**2,015.6**	**26.7%**	**2,309.8**	**10.6%**	**4,863.7**	**3,896.1**	**24.8%**
Cost of materials consumed	282.6	243.2	16.2%	256.0	10.4%	538.6	457.3	17.8%
Gross Profit	**2,271.2**	**1,772.4**	**28.1%**	**2,053.9**	**10.6%**	**4,325.1**	**3,438.8**	**25.8%**
Gross Profit (%)	**88.9%**	**87.9%**	**100 bps**	**88.9%**	**1 bps**	**88.9%**	**88.3%**	**66 bps**
Employee benefits expense	383.5	322.6	18.9%	374.8	2.3%	758.2	638.7	18.7%
Other expenses	760.3	631.6	20.4%	693.7	9.6%	1,454.0	1,246.6	16.6%
EBITDA	**1,127.5**	**818.3**	**37.8%**	**985.4**	**14.4%**	**2,112.9**	**1,553.6**	**36.0%**
EBITDA Margin (%)	**44.1%**	**40.6%**	**355 bps**	**42.7%**	**149 bps**	**43.4%**	**39.9%**	**357 bps**
Other income	49.5	62.5	-20.8%	85.3	-42.0%	134.8	133.0	1.4%
Depreciation and amortization expense	269.0	222.7	20.8%	251.2	7.1%	520.2	431.6	20.5%
EBIT	**908.0**	**658.1**	**38.0%**	**819.5**	**10.8%**	**1,727.4**	**1,255.0**	**37.6%**
Finance costs	113.8	78.3	45.4%	110.0	3.4%	223.8	153.1	46.2%
Profit before Exceptional Items & Tax	**794.2**	**579.8**	**37.0%**	**709.4**	**11.9%**	**1,503.6**	**1,101.9**	**36.5%**
Exceptional Items	0.0	0.0	-	0.0	-	0.0	0.0	-
Profit before Tax	**794.2**	**579.8**	**37.0%**	**709.4**	**11.9%**	**1,503.6**	**1,101.9**	**36.5%**
Tax expenses	199.4	147.0	35.7%	178.4	11.8%	377.9	283.2	33.4%
Profit before Minority Interest	**594.7**	**432.8**	**37.4%**	**531.0**	**12.0%**	**1,125.7**	**818.7**	**37.5%**
Minority Interest	0.0	0.0	-	0.0	-	0.0	0.0	-
Profit after Tax (PAT)	**594.7**	**432.8**	**37.4%**	**531.0**	**12.0%**	**1,125.7**	**818.7**	**37.5%**
PAT Margin (%)	**23.3%**	**21.5%**	**181 bps**	**23.0%**	**30 bps**	**23.1%**	**21.0%**	**213 bps**
EPS – Basic (INR)*	5.8	4.2	37.2%	5.2	11.9%	10.9	8.0	37.4%

**Not annualized*

Sustained Momentum Observed Across the Wellness Segment

1. High Volume of Wellness testing being observed in younger population due to **increased awareness** & **growing chronic disease burden** due to stress, sedentary life & shift in lifestyle patterns

2. Adoption of wellness testing is scaling across markets, with **Tier 2** and **Tier 3 cities** emerging as key growth drivers

3. **Digital promotions** by the organised players along with third party healthcare platforms have also aided in increased footfalls for wellness packages

4. **Faster report turnaround times (TAT),** coupled with the **convenience** of **home testing,** have been key drivers of growth






27.1%

Q2 FY27 YOY Growth %

27.4%

H1 FY27 YOY Growth %







VIJAYA DIAGNOSTIC CENTRE®

Key Developments

1 Launched State-of-the-Art Flagship Hub in JP Nagar, Bengaluru (1/2)

Inaugurated State-of-the-Art Hub in JP Nagar in the 2nd week of July, 2026 in line with our strategy of expanding organically in Bengaluru






10,000+ sq.ft. Hub houses advanced equipment like Wide Bore 3T MRI and Digital PET with 160 slice cardiac CT

The Wide Bore 3T Omega MRI is first of its kind in Karnataka, offering significantly faster scan times while delivering enhanced patient comfort and a superior imaging experience

1 Launched State-of-the-Art Flagship Hub in JP Nagar, Bengaluru (2/2)

Inaugurated State-of-the-Art Hub in JP Nagar in the 2nd week of July, 2026 in line with our strategy of expanding organically in Bengaluru











10,000+ sq.ft. Hub also houses full-fledged lab which will serve as the central lab for entire Bengaluru region

Strategically located in the middle of several super-specialty hospitals

3 Inaugurated 2 Spokes in Hyderabad (1/2)

Inaugurated a spoke in Kothapet, Hyderabad in line with our strategy of building dense network and deepening marketing penetration





3 Inaugurated 2 Spokes in Hyderabad (2/2)

Inaugurated a spoke in Moghalpura, Hyderabad in line with our strategy of building dense network and deepening marketing penetration





4 Strategic Foray into Assam with the Acquisition of Arya Wellness Centre



TRANSACTION CONSIDERATION

₹46.2 Cr.

8-9x

FY26 Adjusted EBITDA [1]


The Seller is currently in the process of fulfilling the Conditions Precedent (CPs). We expect to commence operations under Vijaya from 1st January 2027

1. IND AS EBITDA

4 Expanding our Footprint with Entry into North-East

Existing


OUR NETWORK



6 States


VIJAYA DIAGNOSTIC CENTRE | VIJAYA PH DIAGNOSTIC CENTRE | medinova diagnostic services limited

Synergistic Expansion



Established Platform

Post Acquisition



7 States

VIJAYA DIAGNOSTIC CENTRE | VIJAYA PH DIAGNOSTIC CENTRE | medinova diagnostic services limited | ARYA WELLNESS CENTRE

Acquisition of Arya Wellness, provides Vijaya with an established operating platform in a strategically synergistic market, strengthening our Eastern India presence and creating a strong foundation for expansion across the North-East

Leveraging the Transformative Power of AI for CT KUB Cases Reporting

VIJAYA DIAGNOSTIC CENTRE

Automated Stone Detection & 3D Localization

- **Auto-locates & measures stones**
- Precise **3D localization** of stones aids in anatomical orientation

Intelligent Differentiation


- Distinguishes **true kidney stones from harmless pelvic vein calcifications and vascular spots in arteries**

Improving Radiologist's Productivity & Accuracy

- Prioritises urgent scans - **flagging positive cases**
- **Cuts reporting time** with precise volume & density data
- Reduces risk of **missing small or faint stones**

Enhances Precision Surgical Planning for Urologist

- Precise volume and density data helps in choosing the **right intervention**
- Accurate **"stone burden" calculation** allows for better prediction of stone-free rates after a single procedure




Key Slices:

Stone Composition:

- Soft (Below 200 HU)
- Uric (200-600 HU)
- Calcium (Above 600 HU)

Incorporating AI has enhanced the surgical planning experience, and improves operational efficiency across the entire Urology pathway

AI-Powered Dental Diagnostics for Precision Care



Original Image





Image With Anatomy And Conditions



- AI dental diagnostics platform delivers **high-precision 2D/3D radiograph analysis, predictive care, and clinical decision support**
- **AI-based 2D & CBCT scan analysis** for faster, more accurate diagnostics
- Enhances **patient outcomes** & trust with **visual decisions support**
- Enables **predictive care** & **personalized treatment planning**




VIJAYA DIAGNOSTIC CENTRE®

Strategic Expansion

Expanding Strategically in Alignment with our Vision

Inorganic Expansion Strategy

- Successfully acquired PH, Pune's largest B2C integrated diagnostic chain
- This strategic acquisition seamlessly aligns with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values
- Operationalized 2 hubs in Ambegaon & Kalyani Nagar and 2 spokes under Vijaya PH Brand, following the acquisition
- Planning to add 1-2 hubs in the next 12 months



East India Strategy

- Planning to add 1 Hub in the next 12 months to take our overall network to 8 in East India
- Employing our proven hub and spoke model, aim to replicate our success in East India by creating a dense network


Expansion into Neighbouring State


- Planning to add 3 hubs in FY27 to take our overall hub network to 6 hubs in Karnataka
- Actively scouting for locations to add multiple hubs and spokes in FY28 and FY29

Core Market Strategy

- Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles, strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed
- Added a hub centre in Hyderabad in Q1 FY27 and planning to enter 2 key cities of AP - Vijayawada & Guntur & add multiple spokes across our core geography in the next 12 months

Expansion Plans - Upcoming Hubs and Spokes Centres

Geography	Launched in H1 FY27	Upcoming	Tentative Timelines for Commencement
	1 Hub 4 Spokes	4 Spokes	H2 FY27
	2 Spokes	1 Hub 1 Spoke	H2 FY27 H2 FY27
	1 Hub	2 Hubs 1 Spoke	H2 FY27 H2 FY27
	-	1 Spoke	H2 FY27
	1 Spoke		



* In addition to the above expansion, we are planning to launch 3rd flagship centre in the western corridor of Hyderabad




VIJAYA DIAGNOSTIC CENTRE®

Company Overview

Vijaya at a Glance

Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 168 state-of-the-art centres spread across 27 cities & towns

Evolved from a regional player to a player with presence in multiple geographies …



… While retaining its core values of providing Quality, Reliable & Accurate Diagnostic services at Affordable prices

VIJAYA DIAGNOSTIC CENTRE

40+
Years of Vintage

18 labs with NABL Accreditation

Founded by Mr. Surendranath Reddy in 1981 and currently led by Ms. Suprita Reddy

27
Cities and towns across India

Largest B2C integrated Player in India

400+
Doctors

Radiologist & Pathologist network

~5.00 Mn
Footfalls (1)

Trusted by every Age group

~18.28 Mn
Tests (1)

Most preferred Diagnostic Centre

1. Footfall and Tests for the 12 months ended 30-Sep-26

Our Journey

1981

- Vijaya Diagnostic Centre incorporated in Hyderabad

2007

- Became 1st independent diagnostic centre in South India to offer PET CT from Wipro GE Healthcare

2012

- Recognized as one of the Best Imaging centres in Hyderabad by The Week

2016

- Received investment from Karakoram Limited & Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF1

2018

- Awarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership award

2019

- Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group

2020

- One of the earliest private diagnostic service providers to be approved for COVID RT-PCR testing by ICMR*

2021

- Successfully listed on Indian Stock Exchanges (NSE* & BSE*)
- 1st independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare

2022

- Awarded one of the Best Healthcare Brands 2022 by The Economic Times
- Won the Healthcare Leadership Awards 2022
- Awarded Pride of India Brands Award – The Best of South Awards 2022

2023

- Successfully launched the first center in Kolkata under the "Vijaya“ brand name
- Acquired 100% stake in P.H. Diagnostics and forayed into Pune
- Awarded Best Brand at ET Edge Awards 2023

2024

- Transitioned to AI Radiology Software - “Augmento”
- Awarded Icon in Integrated Diagnostic Services by Times Health Excellence
- Recognized as Fastest Growing Brands at Asian Business & Social Forum 2024, Dubai

2025

- Forayed into Bengaluru market by launching 2 hubs in Yelahanka and HSR Layout under the “Vijaya” brand name


* ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

Integrated Diagnostics Player Offering One-Stop Solution

Complete Range of Diagnostic Services under One Roof


Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience

Pathology (1)





Radiology (1)







1. Revenue mix for Q2 FY27

Dominant Position in Telangana & AP Markets with a Strong Brand Recall

Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets



Present in Key Geographies of AP & Telangana



67 (1) %

Hyderabad Revenue Contribution

20 (1) %

RoAPT Revenue Contribution


A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests

1. For Q2 FY27


Existing Centres | Upcoming Centres | Upcoming Centre in FY28

Strong Traction observed in Newer Geographies (1/3)


Differentiated offering has accelerated Vijaya's success in new geographies



West Bengal Network



Greater Kolkata Area Network




Faster break-even's enable replication of densification strategy in newer geographies


Existing Centres Upcoming Centres

Strong Traction observed in Newer Geographies (2/3)

Differentiated offering has accelerated Vijaya Brand's success in new geographies



Pune Network




Faster break-even's enable replication of densification strategy in newer geographies


Existing Centres Upcoming Centres

Strong Traction observed in Newer Geographies (3/3)

Differentiated offering has accelerated Vijaya Brand's success in new geographies




Bengaluru Network




Faster break-even's enable replication of densification strategy in newer geographies


Existing Centres Upcoming Centres


Driving Geographical Diversification through Strategic Expansion




Geographical Revenue Mix










Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience

RoAPT - Rest of AP and Telangana


Boosting Accessibility with Best-in-class Online Services & Home Collections


Online Services

Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings



- Access to reports online & historical medical records
- Intuitive[1] & user-friendly interface
- Agile customer service team
- High Brand salience
- High customer stickiness
- Organic word of mouth growth





Home Collections

Elevating Customer Experience through Home Collections

Seamless & Efficient process + *Temperature Controlled Logistics* + *High standards of hygiene maintained*



Pre-sealed & sterilized single-use home kit + *Reaches Lab within 2 hours [2]*

1. Patient can track his / her health trends over time 2. Post Collection

Robust Technical Capabilities with State-of-the-art IT Infrastructure

41 CT Machines

10 PET CT / Gamma machines

44 MRI Machines

400+ Radiologists, Lab Doctors & Physicians

10 NABH Accreditations

18 NABL Accreditations

Key Suppliers

SIEMENS, BECKMAN COULTER, PHILIPS, WIPRO, GE, HOLOGIC, UNITED IMAGING, BIOMÉRIEUX, Wipro GE Healthcare

- Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Advanced Software to Manage Clinical Data

Advance Laboratory Information Management System (LIMS)

Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling…

Standardization across our operations

Closely track key performance metrics and maintain the **Turn-Around Time (TAT)**

Reduce incidence of errors due to **Low Human Intervention**

Monitor Technical Operations

Provide **Uniform Experience** to customers from booking appointments to accessing reports online

Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipment in India which has helped in offering high quality services

Note: Data above is as at 30-Sep-26

Experienced Board of Directors



Founder & Chairman

Dr. S. Surendranath Reddy

- ✓ 40+ years of experience
- ✓ Holds Bachelor's degree in Medicine and Doctor of Medicine in Radiology



Managing Director & CEO

Ms. Suprita Reddy

- ✓ 22+ years of experience
- ✓ Awarded Women Leadership Award in Healthcare by ABP



Executive Director

Mr. Sunil Chandra Kondapally

- ✓ 22+ years of experience
- ✓ Holds Bachelor's degree in Electrical Engineering from Florida State University



Non-Executive Director

Ms. S Geeta Reddy

- ✓ 35+ years of experience
- ✓ BOD at Sura Agritech, Iffco Kisan, Namrata Diagnostics, etc.
- ✓ LLB from Osmania University



Non-Executive Independent Director

Mr. S. Murthy Chavali

- ✓ 35+ years of experience
- ✓ Ex-CEO - Aurigene Discovery Tech
- ✓ MBA from IIM, Bangalore & BTech from IIT, Madras



Non-Executive Independent Director

Mr. Dipinder Singh Sekhon

- ✓ 25+ years of experience
- ✓ Founder of AI Healthcare company iKites.ai
- ✓ MPA from LSE(1)
- ✓ BTech & MTech from IIT, Delhi



Non-Executive Independent Director

Mr. Ravi Shankararamiah

- ✓ 40+ years of experience and designated as Senior Advocate by High Court of Andhra Pradesh
- ✓ Graduated magna cum laude from USC, LA(2) in MS



Non-Executive Independent Director

Dr. Sasikala Paruchuri Kola

- ✓ 30+ years of experience as a Gynaecologist & Obstetrician
- ✓ Leadership roles in FOGSI (3) and OGSH(4)
- ✓ MD & DGO from Osmania Medical College

1. Master of Public Administration in Public & Economic Policy from London School of Economics 2. University of Southern California, Los Angeles 3. Federation of Obstetric and Gynaecological Societies of India 4. Obstetric and Gynaecological Society of Hyderabad

Stellar Management Team



Founder & Chairman

Dr. S. Surendranath Reddy



Managing Director & CEO

Suprita Reddy



Executive Director

Sunil Chandra Kondapally



Chief Operating Officer

Sivaramaraju Vegesna, CFA



Chief Financial Officer

Narasimha Raju K.A



Director - Laboratory

Dr. Kiran B




Director - Radiology

Dr. V Vijayanand

Shareholding Pattern as at 30th September, 2026

Shareholding Pattern as at 30th September, 2026




DIIs: Mutual Funds, AIFs and QIBs
FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs
Others: Retail, Bodies Corporate and others

Key Investors

Doctors Connect Program in Q2 FY27









Awards & Accolades

Best Healthcare Brands 2026 recognized by ET Edge

Most Preferred Workplace 2026-27 recognized by Marksmen Daily



Icon in Integrated Diagnostic Services by Times Health Excellence TS & AP 2025



Best Diagnostic Centre awarded at HMTV Healthcare Awards 2025



Icon in Integrated Diagnostic Services by Times Health Excellence 2024 - TS & AP



Best Healthcare Brands' 2025 recognized by ET Edge



Most Trusted Brand of India 2024-25 awarded by Marksmen Daily – 4th edition




Most Preferred Workplace for Women 2024 – 25 recognized by Marksmen Daily



Fastest Growing Brands 2023-24 awarded at Asian business & Social Forum 2024, Dubai



Best Healthcare Brands' 2024 recognized by ET Edge



Best Brand awarded at ET Edge Awards 2023



Fastest Growing Leaders 2023-24 awarded at Asian business & Social Forum 2024, Dubai

Best Healthcare Brands' awarded by Economic Times - 2023



Excellence In Comprehensive Diagnostic Care awarded by ABP Ananda Swasthya Samman



Most Trusted Brand of India awarded by Marksmen Daily – 3rd edition



VIJAYA DIAGNOSTIC CENTRE®


Annexure

State-of-the-art Infrastructure (1/3)





State-of-the-art Infrastructure (2/3)



State-of-the-art Infrastructure (3/3)



Advanced Equipment in Place to Deliver High Quality Services (1/2)










Advanced Equipment in Place to Deliver High Quality Services (2/2)











Robust Operational Metrics


Diagnostic Centre (Nos)




Footfalls (Mn)




Tests Performed (Mn)




Test per Footfall (Nos)



Revenue per Test (INR)




Revenue per Footfall (INR)




Consistent Financial Performance

(INR Mn)


Revenue




EBIDTA




PAT



EBIDTA Margin (%)



PAT Margin (%)




Integrated business model with high B2C concentration (~92%) and a strong brand recall has resulted in Industry leading margins


Note: *With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value ("WDV") method to Straight Line Method ("SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets. Due to the aforesaid change, the PAT for the year Financial year ended March 31, 2023 and Financial year ended March 31, 2024 was higher by Rs 67.7 Mn and Rs 290.8 Mn respectively*

Sustainable Cash Generation & Increasing Return Ratios


Surplus Cash (INR Mn)




CFO (1) / EBIDTA (%)



RoCE Pre-Tax (2) (%)



RoE (3) (%)



1. CFO = Cash flow from Operations
2. ROCE (Pre-tax): (PBIT ex Other income) / (Average Networth + Average Long Term Lease Liabilities – Average Surplus Cash)
3. ROE: PAT / Average Networth

Consolidated Profit & Loss Account

(INR Mn)

Particulars	FY22	FY23	FY24	FY25	FY26
Revenue from operations	**4,624**	**4,592**	**5,478**	**6,814**	**8,142**
Cost of materials consumed	715	589	654	848	947
Employee benefits expense	707	785	902	1,122	1,307
Other expenses	1,165	1,398	1,712	2,113	2,518
EBITDA	**2,037**	**1,820**	**2,209**	**2,732**	**3,369**
EBITDA %	**44.1%**	**39.6%**	**40.3%**	**40.1%**	**41.4%**
Other income	128	142	208	183	208
Depreciation and amortization expense	527	617	570	706	918
EBIT	**1,638**	**1,344**	**1,847**	**2,209**	**2,659**
Finance costs	165	209	240	267	332
Profit before tax and exceptional items	**1,474**	**1,135**	**1,607**	**1,942**	**2,327**
Exceptional items	-	-	21	10	-
Profit before Tax	**1,474**	**1,135**	**1,587**	**1,932**	**2,327**
Tax expenses	367	283	390	494	597
Profit after Tax before Minority Interest	1,107	852	1,196	1,438	1,730
Minority Interest	10	5.8	8	-	-
Profit after Tax	**1,097**	**846**	**1,188**	**1,438**	**1,730**
PAT %	**23.7%**	**18.4%**	**21.7%**	**21.1%**	**21.2%**
EPS – Basic (INR)	**10.76**	**8.29**	**11.62**	**13.95**	**16.81**

Consolidated Balance Sheet

(INR Mn)

ASSETS	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
NON-CURRENT ASSETS	**4,436**	**5,777**	**7,714**	**9,664**	**11,851**
Property, plant and equipment	1,966	2,940	3,785	4,469	5,625
Capital work-in-progress	341	271	83	703	343
Goodwill	53	53	1,192	1,192	1,192
Other intangible assets	14	22	207	219	204
Right of use asset	1,672	2,223	2,235	2,768	3,672
Intangible assets under development	1	6	5	0	8
Financial assets					
- Investments	0	0	0	0	0
- Other financial assets	75	90	113	165	481
Deferred tax assets	89	83	29	0	0
Income tax assets	2	2	2	12	2
Other assets	223	85	62	136	324
CURRENT ASSETS	**2,698**	**2,757**	**2,113**	**3,072**	**3,219**
Inventories	43	20	52	49	49
Financial assets					
- Investments	542	1,390	1,091	1,846	2,284
- Trade receivables	98	95	162	148	209
- Cash and cash equivalents	110	242	222	128	397
- Bank balances other than Cash and cash equivalents	1,813	922	508	361	131
- Loans	0	0	0	0	
- Other financial assets	51	36	31	478	80
Other current assets	41	51	46	62	70
TOTAL ASSETS	**7,135**	**8,534**	**9,828**	**12,736**	**15,070**

EQUITY & LIABILITIES	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
EQUITY	**4,695**	**5,466**	**6,599**	**7,991**	**9,572**
Equity share capital	102	102	102	103	103
Instruments entirely equity in nature	-	-	-	-	-
Other equity	4,593	5,364	6,497	7,889	9,469
Non-Controlling Interest					
NON-CURRENT LIABILITIES	**1,778**	**2,406**	**2,500**	**3,119**	**4,260**
Financial liabilities					
- Borrowings	0	0	0	0	0
- Lease liabilities	1,703	2,330	2,391	2,964	4,000
- Other financial liabilities	0	0	0	0	0
Provisions	74	71	106	99	110
Other non current liabilities	1	5	3	3	5
Deferred tax liabilities	-	-	-	53	145
CURRENT LIABILITIES	**661**	**662**	**729**	**1,626**	**1,239**
Financial liabilities					
- Borrowings	6	0	0	0	0
- Lease liabilities	126	145	201	232	226
- Trade payables	216	277	329	331	376
- Other financial liabilities	248	140	114	925	491
Income tax liabilities	9	24	12	35	9
Provisions	21	40	32	60	83
Other current liabilities	35	36	40	44	53
TOTAL EQUITY AND LIABILITIES	**7,135**	**8,534**	**9,828**	**12,736**	**15,070**

Consolidated Cash Flow Statement

(INR Mn)

Particulars	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
Cash Flow from Operating Activities					
Profit before Tax	1,474	1,135	1,587	1,932	2,327
Adjustment for Non-Operating Items	572	683	599	786	1,070
Operating Profit before Working Capital Changes	**2,046**	**1,818**	**2,186**	**2,718**	**3,397**
Changes in Working Capital	-67	90	-14	-74	-168
Cash Generated from Operations	**1,979**	**1,908**	**2,172**	**2,644**	**3,228**
Less: Direct Taxes paid	-399	-262	-339	-399	-522
Net Cash from Operating Activities	**1,580**	**1,646**	**1,833**	**2,245**	**2,706**
Purchase and construction of property, plant and building (net)	-1,223	-1,248	-880	-955	-1,827
Acquisition of subsidiary	-	-	-1,475	-	-
Investments (net)	-127	734	530	-893	57
Others	120	887	401	29	28
Cash Flow from Investing Activities	**-1,231**	**-1,096**	**-1,423**	**-1,819**	**-1,742**
Cash Flow from Financing Activities	**-306**	**-419**	**-445**	**-520**	**-695**
Net increase/ (decrease) in Cash & Cash equivalent	**44**	**131**	**-36**	**-94**	**269**
Cash & Cash Equivalents at the beginning of the period	67	110	258	222	128
Cash & Cash equivalents at the end of the period	**110**	**242**	**222**	**128**	**397**

Surplus Cash

Particulars	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
Investments*	542	1,390	1,092	1,846	2,284
Cash and cash equivalents	110	242	222	128	397
Bank balances other than Cash and cash equivalents**	1,813	922	537	843	512
Less: Deferred Capital Creditors				750	323
Total	**2,465**	**2,554**	**1,851**	**2,067**	**2,869**

*Current investments + investments with maturity more than 12 months (part of other non-current financial assets) ** Includes all the fixed deposits



VIJAYA DIAGNOSTIC CENTRE®

Thank You

For further information please contact:

Mr. Dhiren Gala
Head - Investor Relations & Corporate Development
+91 90598 93206

dhiren.g@vijayadiagnostic.in
ir@vijayadiagnostic.in

www.vijayadiagnostic.com